PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.53%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
-21.01%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.76%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-10.76%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
0.96%
D&A growth 0-5% reflects moderate asset expansion. Benjamin Graham would check if growth drives future value.
10.97%
EBITDA growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Operating income growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
104.37%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
11.35%
Pre-tax income growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
305.13%
Tax expense growth above 20% signals concerning expansion. Seth Klarman would scrutinize tax strategy.
11.35%
Net income growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
31.03%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
31.72%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
29.31%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
29.44%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.